The PSOC Administrative Core will manage and coordinate all Center research and activities and serve as the liaisons between the Centers and the Network. The DFCI-PSOC has organized a leadership structure to provide expertise and fully support all initiatives within the DFCI-PSOC and PSOC network. The leadership consists of two PIs, Franziska Michor, PhD, and Eric Holland, MD, PhD. Support personnel consists of the Center Administrator/Education Director, Jessica Daniels, MA, who possesses strong project management capabilities. The PSOC leadership and support personnel, also known as the Administration, will work collectively to support and accomplish the proposed research projects, core, educational and training unit and, pilot/trans-network projects, and program evaluation. The Center Advisory Committee (CAC) will bring together investigators with expertise in both the physical sciences and the basic sciences to form a group of voting members. Specifically, the CAC will be made up of the following members: two physical sciences members, Franziska Michor, PhD (PI), and Rong Fan, PhD (core leader); two biological/clinical members, Eric Holland, MD/PhD (PI) and David Scadden, MD (Project 1 leader), a NCI representative, and two external advisors. The staff of the PSOC Administration is committed to provide organizational support and leadership to permit the research projects and core to accomplish their goals and to distribute the accomplishments of each PSOC lab among the PSOC investigators. As such, we have organized appropriate and effective administrative and organizational structures to effectively manage and coordinate all Center research and activities including overall organization, management and communication, trans-network and pilot projects, network activities, and resource sharing.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
3U54CA193461-05S1
Application #
10134497
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Zahir, Nastaran Z
Project Start
Project End
Budget Start
2019-05-01
Budget End
2021-04-30
Support Year
5
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Ozawa, Tatsuya; Arora, Sonali; Szulzewsky, Frank et al. (2018) A De Novo Mouse Model of C11orf95-RELA Fusion-Driven Ependymoma Identifies Driver Functions in Addition to NF-?B. Cell Rep 23:3787-3797
Cimino, Patrick J; Kim, Youngmi; Wu, Hua-Jun et al. (2018) Increased HOXA5 expression provides a selective advantage for gain of whole chromosome 7 in IDH wild-type glioblastoma. Genes Dev 32:512-523
Stein, Shayna; Zhao, Rui; Haeno, Hiroshi et al. (2018) Mathematical modeling identifies optimum lapatinib dosing schedules for the treatment of glioblastoma patients. PLoS Comput Biol 14:e1005924
Hinohara, Kunihiko; Wu, Hua-Jun; Vigneau, Sébastien et al. (2018) KDM5 Histone Demethylase Activity Links Cellular Transcriptomic Heterogeneity to Therapeutic Resistance. Cancer Cell 34:939-953.e9
Maley, Carlo C; Aktipis, Athena; Graham, Trevor A et al. (2017) Classifying the evolutionary and ecological features of neoplasms. Nat Rev Cancer 17:605-619
Dasgupta, Arko; Lim, Andrea R; Ghajar, Cyrus M (2017) Circulating and disseminated tumor cells: harbingers or initiators of metastasis? Mol Oncol 11:40-61
Gil Del Alcazar, Carlos R; Huh, Sung Jin; Ekram, Muhammad B et al. (2017) Immune Escape in Breast Cancer During In Situ to Invasive Carcinoma Transition. Cancer Discov 7:1098-1115
Kievit, Forrest M; Wang, Kui; Ozawa, Tatsuya et al. (2017) Nanoparticle-mediated knockdown of DNA repair sensitizes cells to radiotherapy and extends survival in a genetic mouse model of glioblastoma. Nanomedicine 13:2131-2139
Pattwell, Siobhan S; Holland, Eric C (2017) Putting Glioblastoma in Its Place: IRF3 Inhibits Invasion. Trends Mol Med 23:773-776
Peinado, Héctor; Zhang, Haiying; Matei, Irina R et al. (2017) Pre-metastatic niches: organ-specific homes for metastases. Nat Rev Cancer 17:302-317

Showing the most recent 10 out of 36 publications